RSV Prevention Tied to Lower Infant Acute Care Use - Takeaways - MDSpire
Advertisement
RSV Prevention Tied to Lower Infant Acute Care Use
Data suggest fewer respiratory syncytial virus–associated hospitalizations and emergency department visits among the youngest infants during the second season of routine prevention product use.
A Washington state study found a 43% decrease in RSV-associated hospitalizations and ED visits among infants under 7 months during the second year of nirsevimab use.
2
The study analyzed 16,775 RSV-related encounters, revealing a significant decline in rates from 6.1 to 2.6 per 100 population between the 2022-2023 and 2024-2025 seasons.
3
Immunization coverage for infants increased, with approximately 39% immunized in the first season and coverage doubling in the second season, contributing to the observed impact.
4
The estimated population impact varied by county, with decreases ranging from 15.5% to 57.7%, and was greater among White infants compared to Native Hawaiian or Other Pacific Islander infants.
5
Clesrovimab, a new monoclonal antibody, was approved in June 2025, offering a potential expansion of RSV prevention strategies with easier storage and dosing.
